ORIC Pharmaceuticals, Inc. (ORIC)
| Market Cap | 1.36B +34.0% |
| Revenue (ttm) | n/a |
| Net Income | -140.35M |
| EPS | -1.35 |
| Shares Out | 103.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,493,809 |
| Open | 13.27 |
| Previous Close | 13.18 |
| Day's Range | 12.94 - 13.49 |
| 52-Week Range | 7.23 - 14.93 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 20.67 (+57.07%) |
| Est. Earnings | Nov 12, 2026 |
About ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutat... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ORIC stock is "Strong Buy." The 12-month stock price target is $20.67, which is an increase of 57.07% from the latest price.
News
Oric Pharmaceuticals initiated with a Buy at BTIG
BTIG analyst Jeet Mukherjee initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $26 price target. Oric’s rinzimetostat has a potential best-in-class safety profile over Pfizer’s (P...
Oric Pharmaceuticals initiated with a Buy at BTIG
BTIG analyst Jeet Mukherjee initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $26 price target
ORIC Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing two late-stage oncology programs: rinzimetostat for prostate cancer, with a phase III trial underway and strong safety differentiation, and enozertinib for lung cancer, targeting brain metastases with upcoming data at ESMO. Both programs address large markets, are well-funded through 2028, and have clear strategies for further development and potential partnerships.
ORIC Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Late-stage clinical programs focus on prostate and lung cancer, with HIMALAYA-1 phase III underway and additional studies planned. Positive readouts from Pfizer’s trials are expected to de-risk the PRC2 inhibitor class. Strong commercial potential and a cash runway into 2028 support ongoing development.
ORIC Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Two late-stage oncology programs are advancing, with rinzimetastat in phase III for prostate cancer and enozertinib targeting lung cancer. Key differentiators include safety and potential resistance advantages, with major data readouts and program updates expected over the next 12–18 months.
ORIC Pharmaceuticals Slides: Company presentation
ORIC Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing tre...
Oric Pharmaceuticals price target raised to $27 from $25 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $27 from $25 and keeps a Buy rating on the shares post the Q2 report.
Oric Pharmaceuticals reports Q2 EPS (38c), consensus (36c)
“The recent initiation of Himalayas-1, a global Phase 3 registrational trial, brings us closer to delivering a potentially practice-changing therapy for patients with prostate cancer,” said Jacob M. C...
ORIC® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid...
ORIC Pharmaceuticals Earnings release: Q2 2026
ORIC Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
ORIC Pharmaceuticals Quarterly report: Q2 2026
ORIC Pharmaceuticals has published its Q2 2026 quarterly earnings report on August 3, 2026.
ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026
Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalaya...
Oric Pharmaceuticals initiates Himalayas-1 trial
Oric Pharmaceuticals (ORIC) announced the initiation of the Himalayas-1 global Phase 3 registrational trial in patients with metastatic castration-resistant prostate cancer previously treated with abi...
ORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayer
Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Bayer to provide darolutamid...
Oric Pharmaceuticals resumed with a Buy at Stifel
Stifel analyst Laura Prendergast resumed coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $14 price target A Phase 3 trial for lead asset rinzimetostat is expected to initiate…
ORIC Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The conference highlighted imminent initiation of a 600-patient phase III prostate cancer study, with a finalized protocol and dose, and emphasized rinzimetostat's competitive efficacy and superior safety profile. The EGFR program demonstrated strong CNS activity and best-in-class potential, while robust cash reserves support clinical plans into 2028.
ORIC Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
Two late-stage oncology programs are advancing, with rinzimetostat set for imminent phase III launch in prostate cancer and enasertib data expected in the second half of 2024. Rinzimetostat shows strong safety differentiation versus competitors, and regulatory clearance has been secured for its pivotal trial.
Oric Pharmaceuticals moved to Buy rating at Goldman Sachs
Goldman Sachs moved Oric Pharmaceuticals (ORIC) to a Buy rating and $15 price target from its Early Stage Biotech designation. The company’s clinical data which demonstrated a “potentially differentia...
ORIC Pharmaceuticals Slides: Company presentation
ORIC Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 14, 2026.
Oric Pharmaceuticals price target lowered to $16 from $17 at Citi
Citi lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $16 from $17 and keeps a Buy rating on the shares.
Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c)
“The first quarter marked a pivotal step for ORIC as we selected our Phase 3 dose for rinzimetostat, reported data supporting a potential best-in-disease profile, and moved toward the initiation…
ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates
Announced selection of rinzimetostat RP3D in combination with darolutamide for Himalayas-1 Phase 3 global registrational trial in post-abiraterone mCRPC, expected to initiate in 1H 2026
ORIC Pharmaceuticals Earnings release: Q1 2026
ORIC Pharmaceuticals released its Q1 2026 earnings on May 4, 2026, summarizing the period's financial results.